Tech Company Financing Transactions
Codagenix Funding Round
Codagenix closed a $2 million Series A funding round on 6/15/2015. Investors included Topspin Partners.
Transaction Overview
Company Name
Announced On
6/15/2015
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Series A
Investors
Topspin Partners (Jove Equity)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Bioscience Park Dr.
Farmingdale, NY 11735
USA
Farmingdale, NY 11735
USA
Phone
Undisclosed
Website
Email Address
Overview
Codagenix utilizes our breakthrough platform technology termed SAVE (Synthetic Attenuated Virus Engineering) to construct live-attenuated viral vaccines against multiple targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Coleman
Chief Medical Officer
Sybil Tasker
President
Steffen Mueller
VP - Bus. Development
Anna Kushnir
Browse more venture capital transactions:
Prev: 6/15/2015: nChannel venture capital transaction
Next: 6/15/2015: Sequent Software venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs